US equities
|
SPCX
$167.03
▲+5.08%
NVDA
$237.26
▲+1.41%
MU
$1,065.55
▼-0.87%
TSLA
$378.05
▲+2.01%
MSFT
$525.21
▲+1.48%
INTC
$116.55
▼-2.33%
SNDK
$1,712.80
▼-0.42%
META
$745.72
▲+2.42%
SPCX
$167.03
▲+5.08%
NVDA
$237.26
▲+1.41%
MU
$1,065.55
▼-0.87%
TSLA
$378.05
▲+2.01%
MSFT
$525.21
▲+1.48%
INTC
$116.55
▼-2.33%
SNDK
$1,712.80
▼-0.42%
META
$745.72
▲+2.42%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Foundation Medicine
< Previous
1
2
3
Next >
Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use
January 09, 2023
From
Foundation Medicine
Via
Business Wire
FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib)
January 04, 2023
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients
December 21, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Launches FoundationReport+™, a New Digital Reporting Experience to Streamline Precision Cancer Care
November 14, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
September 21, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
September 12, 2022
From
Foundation Medicine
Via
Business Wire
Tickers
RLAY
Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care
September 06, 2022
From
Foundation Medicine
Via
Business Wire
Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer
August 08, 2022
From
Foundation Medicine
Via
Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for Rozlytrek® (entrectinib)
June 09, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Announces Strategic Collaboration with Arvinas
June 05, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy
June 03, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine and Collaborators to Share More Than 20 Abstracts Featuring New Data at the 2022 American Society of Clinical Oncology Annual Meeting Highlighting How Molecular Profiling is Helping to Shape the Future of Personalized Cancer Care
May 26, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care
April 05, 2022
From
Foundation Medicine
Via
Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer
March 17, 2022
From
Foundation Medicine
Via
Business Wire
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors
February 21, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine’s ctDNA Monitoring Assay, FoundationOne®Tracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration
February 15, 2022
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for RETEVMO® and Loxo Oncology at Lilly’s Pipeline Programs
February 09, 2022
From
Foundation Medicine
Via
Business Wire
FoundationOne®CDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma
December 08, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Now an In-Network Provider for Humana Military and Health Net Federal Services
October 28, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Appoints Dymeka Harrison as Chief Commercial Officer
October 13, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Appoints Mia Levy, MD, PhD as Chief Medical Officer
September 21, 2021
From
Foundation Medicine
Via
Business Wire
Science 37® and Foundation Medicine Partner to Enable Interventional Home-Based Clinical Trials in Oncology
September 08, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Announces Partnership With Epic to Streamline Access to Genomic Insights for Precision Cancer Care
August 26, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Appoints Sanket Agrawal as Chief BioPharma Business Officer
August 04, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Expands Indication for FoundationOne®Liquid CDx to be Used as a Companion Diagnostic for TABRECTA® (capmatinib)
July 15, 2021
From
Foundation Medicine
Via
Business Wire
FoundationOne®CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG® (brigatinib) to Identify Patients with ALK positive Metastatic Non-Small Cell Lung Cancer
July 01, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine and Flatiron Health Announce First-of-its-Kind Integration of Genomic Profiling Into OncoEMR®
June 29, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Collaborates on Research Published in The New England Journal of Medicine That Identifies Resistance to KRAS Inhibitors and Underscores Need for Novel Therapeutic Strategies
June 24, 2021
From
Foundation Medicine
Via
Business Wire
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
June 08, 2021
From
Foundation Medicine
Via
Business Wire
Tickers
NTRA
New Study Results Presented by Foundation Medicine and Collaborators at ASCO21 on Ancestry-Based Disparities in Prostate Cancer Care Underscore Importance of Equitable Access to Precision Medicine Advances
June 04, 2021
From
Foundation Medicine
Via
Business Wire
< Previous
1
2
3
Next >
